1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6DBE5C4C5CF576B190025868F002E2FE1
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/disease-awareness-program-excellence-structure-activities-resources-needed-effective-pipeline-suppor-reportt?opendocument
18
19opendocument
203.238.132.225
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Product Launch Influences on Market Entry

Disease Awareness Program Excellence: Structure, Activities, and Resources Needed for Effective Pipeline Support

ID: PSM-377


Features:

11 Info Graphics

42 Data Graphics

850+ Metrics

12 Narratives


Pages: 63


Published: 2021


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Disease state awareness campaigns are critical for helping biopharma manufacturers to reach HCPs and patients, particularly before a product is approved. These awareness campaigns play an especially prominent role in helping the treatment ecosystem understand diseases that with traditionally fewer therapies available.

While some organizations have demonstrated strong acumen in their disease awareness programs, many drug manufacturers struggle to effectively connect their campaigns to their targeted audiences, stumble on message timing, and fail to allocate sufficient resources.

Best Practices, LLC undertook this benchmarking research to spotlight effective practices around the timing, investment, and top activities for successful disease awareness programs. This report presents a slew of insights, best practices, and pitfalls that top biopharma organizations have learned from many of their new and recent disease awareness campaigns.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical; Public Relations; Chemical; Health Care; Communications; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Adamas Pharmaceuticals; AstraZeneca; Bayer; Biogen; Catalyst Pharmaceuticals; CSL Behring; Daiichi Sankyo; Eli Lilly and Company; EMD Serono; FleishmanHillard; Fresenius Medical Care; Genentech; Genzyme; Indivior; Merck KGaA; Merck Sharp & Dohme; Myovant Sciences; Nevakar; NexGen Healthcare; Novartis; Prometheus Laboratories; PruGen Pharmaceuticals; Sanofi; Teva Pharmaceutical Industries Ltd; Tokai Pharmaceuticals; Vertex Pharmaceuticals; ZS Pharma

Study Snapshot

Best Practices, LLC engaged 30 leaders from 28 top life sciences organizations in this benchmarking research. Four executives participated in deep-dive operational interviews. Secondary research is occasionally provided for context.

Key topics covered in this report include:

  • Disease awareness program structure
  • Timing of disease awareness activities
  • Budget and spending for disease awareness programs
  • Involvement of Advocacy Groups and Legal in disease awareness
  • Use of social media for disease awareness

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Activities and Alliances
    • Most disease awareness efforts begin during clinical trials and end at launch +3 years
    • Disease awareness activities concentrated on launch year and launch -1 year
  • Social Media
    • Continually monitor and modify social medical activities
    • Message boards and moderators provide great direct feedback to manufacturers
Table of Contents

Sr. No.
Topic
Slide No.
I.
Overview and ObjectivesPg. 3-5
II.
Program Effectiveness: Practices & PitfallsPg. 7-10
III.
Program StructurePg. 11-15
IV.
Tactics and TimingPg. 16-24
V.
Budget and SpendingPg. 25-35
VI.
Involvement of Advocacy Groups and Legal in Disease AwarenessPg. 36-48
VII.
Social MediaPg. 49-58
VIII.
Participant DemographicsPg. 59-62
IX.
About Best Practices, LLCPg. 63

    List of Charts & Exhibits

    I. Program Effectiveness: Practices & Pitfalls

    • Overall effectiveness of disease awareness programs
    • Best practices for maintaining an effective disease awareness program
    • Common pitfalls or stumbling blocks observed as part of a disease awareness program

    II. Program Structure

    • Organizational structure of disease awareness programs – Total benchmark class
    • Organizational structure of disease awareness programs – Large pharma vs. Mid-small pharma, Global teams vs. Country level teams, Single brand teams vs. Portfolio teams
    • Functional involvement and leadership of disease awareness programs
    • Reporting structure and leadership of dedicated disease state awareness group

    III. Tactics and Timing

    • Start and endpoints for disease awareness resourcing – Total benchmark class
    • Start and endpoints for disease awareness resourcing – Large pharma vs. Mid-small pharma
    • Start and endpoints for disease awareness resourcing – Global teams vs. Country level teams
    • Start and endpoints for disease awareness resourcing – Single brand teams vs. Portfolio teams
    • Start and endpoints for disease awareness resourcing – Highly competitive market vs. Less competitive market
    • Interview narratives around the dividends from disease awareness programs
    • Utilization of disease awareness activities and timing of each of these activities
    • Most utilized disease awareness activities

    IV. Budget and Spending

    • Timing of disease awareness investment across development & launch cycle
    • Total budget for disease awareness initiatives, activities and programs during the current budget year – Large pharma vs. Mid-small pharma
    • Peak year disease awareness investment – Large pharma vs. Mid-small pharma
    • Total budget for disease awareness initiatives, activities and programs during the current budget year – Global teams vs. Country level teams
    • Total budget for disease awareness initiatives, activities and programs during the current budget year – Single brand teams vs. Portfolio teams
    • Factors influencing the amount of resources dedicated to disease awareness programs on a product-by-product basis – Total benchmark class
    • Factors influencing the amount of resources dedicated to disease awareness programs on a product-by-product basis – Large pharma vs. Mid-small pharma
    • Factors influencing the amount of resources dedicated to disease awareness programs on a product-by-product basis – Single brand teams vs. Portfolio teams
    • Functions providing funding for disease awareness programs
    • Disease awareness investment for a new product that serves an unmet need or is in a therapeutic area where there are limited choices

    V. Involvement of Advocacy Groups and Legal in Disease Awareness

    • Interview narratives around patient advocacy group relationships
    • Importance of each patient advocacy group activity and support service from a disease awareness program perspective – Total benchmark class
    • Importance of each patient advocacy group activity and support service from a disease awareness program perspective – Global teams vs. Country level teams
    • Importance of each patient advocacy group activity and support service from a disease awareness program perspective – Single brand teams vs. Portfolio teams
    • Best approaches to support disease awareness activities with patient advocacy groups
    • Importance of highly effective patient advocacy group activities and support services from a disease awareness program perspective – Global teams vs. Country level teams
    • Importance of highly effective patient advocacy group activities and support services from a disease awareness program perspective – Highly competitive market vs. Less competitive market
    • Timing of disease awareness activities with patient advocacy groups
    • Level of involvement of legal department in each of the listed disease awareness program areas – Total benchmark class
    • Level of involvement of legal department in each of the listed disease awareness program areas – Global teams vs. Country level teams
    • Level of involvement of legal department in each of the listed disease awareness program areas – Single brand teams vs. Portfolio teams
    • Interview narrative around managing successful programs with legal groups

    VI. Social Media

    • Disease Awareness Activities conducted on social media and timing of first initiation of each activity – Total benchmark class
    • Disease Awareness Activities conducted on social media and timing of first initiation of each activity – Large pharma vs. Mid-small pharma
    • Utilization ranking of social media activities for generating disease awareness
    • Interview narrative around ensuring patient access via social media
    • Interview narrative around getting direct feedback and insights
    • Total investment in social media disease awareness activities during the last fiscal year – Total benchmark class
    • Total investment in social media disease awareness activities and percentage of overall disease awareness budget spent on social media – Large pharma vs. Mid-small pharma
    • Total investment in social media disease awareness activities and percentage of overall disease awareness budget spent on social media – Global teams vs. Country level teams
    • Total investment in social media disease awareness activities and percentage of overall disease awareness budget spent on social media – Single brand teams vs. Portfolio teams

    VII. Participant Demographics

    • Geographic and marketing perspective of participants represented in the study
    • Therapeutic areas represented in the study
    • Job titles of benchmark participants